These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 38814866

  • 1. EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer.
    Yang C, Ma S, Zhang J, Han Y, Wan L, Zhou W, Dong X, Yang W, Chen Y, Gao L, Cui W, Jia L, Yang J, Wu C, Wang Q, Wang L.
    Proc Natl Acad Sci U S A; 2024 Jun 04; 121(23):e2317790121. PubMed ID: 38814866
    [Abstract] [Full Text] [Related]

  • 2. Wnt/β-Catenin Pathway-Mediated PD-L1 Overexpression Facilitates the Resistance of Non-Small Cell Lung Cancer Cells to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Huang Z, Wang J, Xia Z, Lv Q, Ruan Z, Dai Y.
    Discov Med; 2024 Nov 04; 36(190):2300-2308. PubMed ID: 39600284
    [Abstract] [Full Text] [Related]

  • 3. NUAK1-Mediated Phosphorylation of NADK Mitigates ROS Accumulation to Promote Osimertinib Resistance in Non-Small Cell Lung Carcinoma.
    Lin W, Wang N, Wu S, Diao M, Huang Q, Li K, Mei P, Wang X, Liao Y, Meng Y.
    Cancer Res; 2024 Dec 02; 84(23):4081-4098. PubMed ID: 39159134
    [Abstract] [Full Text] [Related]

  • 4. ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers.
    Martin-Vega A, Earnest S, Augustyn A, Wichaidit C, Gazdar A, Girard L, Peyton M, Kollipara RK, Minna JD, Johnson JE, Cobb MH.
    bioRxiv; 2023 Jun 15. PubMed ID: 37398419
    [Abstract] [Full Text] [Related]

  • 5. Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
    Saalfeld FC, Möller J, Christopoulos P, Wenzel C, Rasokat A, Wang XA, Vathiotis I, König D, Illini O, Grohé C, Wiesweg M, Wesseler C, Schubart C, Pelusi N, Rohde G, Overbeck TR, Kirfel J, Alt J, Kauffmann-Guerrero D, Griesinger F, Kulhavy J, Allgäuer M, Klimova A, Schütz M, Aust DE, Hochmair MJ, Rothschild SI, Syrigos KN, Veluswamy R, Michels S, Stenzinger A, Jöhrens K, Wermke M.
    Eur J Cancer; 2024 Dec 15; 213():115065. PubMed ID: 39423775
    [Abstract] [Full Text] [Related]

  • 6. Molecular Interactions of the Plant Steroid Hormone Epibrassinolide on Human Drug-Sensitive and Drug-Resistant Small-Cell Lung Carcinoma Cells.
    Sadava D, Chen S.
    Cancers (Basel); 2024 Nov 13; 16(22):. PubMed ID: 39594767
    [Abstract] [Full Text] [Related]

  • 7. Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway.
    Cuan X, Yang X, Wang J, Sheng J, Wang X, Huang Y.
    Bioorg Chem; 2024 Dec 13; 153():107808. PubMed ID: 39288634
    [Abstract] [Full Text] [Related]

  • 8. ZNF131-BACH1 transcriptionally accelerates RAD51-dependent homologous recombination repair and therapy-resistance of non-small-lung cancer cells by preventing their degradation from CUL3.
    Fan M, Liu Q, Ma X, Jiang Y, Wang Y, Jia S, Nie Y, Deng R, Zhou P, Zhang S, Jiang S, Guan M, Hou Y, Miao Y, Zhang Y, Zhang X.
    Theranostics; 2024 Dec 13; 14(18):7241-7264. PubMed ID: 39629137
    [Abstract] [Full Text] [Related]

  • 9. Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer.
    Hayashi A, Kamio K, Miyanaga A, Yoshida K, Noro R, Matsuda K, Tozuka T, Omori M, Hirao M, Fukuizumi A, Hisakane K, Takeuchi S, Matsumoto M, Kasahara K, Amano T, Honda K, Seike M.
    Anticancer Res; 2024 Dec 13; 44(12):5271-5282. PubMed ID: 39626921
    [Abstract] [Full Text] [Related]

  • 10. Anti-cancer effect of sodium pentaborate in combination with cisplatin on lung cancer cell lines.
    Deniz C, Gedik T, Yüksel B, Cebeci E, Şahin F.
    Mol Biol Rep; 2024 Nov 29; 52(1):28. PubMed ID: 39612011
    [Abstract] [Full Text] [Related]

  • 11. RNA binding protein RBM22 suppresses non-small cell lung cancer tumorigenesis by stabilizing LATS1 mRNA.
    Hou M, Huang Q, Chen S, Lei J, Zhang Y.
    J Mol Histol; 2024 Nov 29; 56(1):15. PubMed ID: 39612045
    [Abstract] [Full Text] [Related]

  • 12. Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.
    Smith MR, Dixon CB, Wang Y, Liu Y, D'Agostino R, Ruiz J, Oliver G, Miller LD, Topaloglu U, Chan MD, Farris M, Su J, Mileham KF, Zhao D, Li W, Sexton T, Lycan T, Haas KM, Grayson JM, Xing F.
    Cancer Res; 2024 Dec 02; 84(23):4002-4016. PubMed ID: 39250241
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC, Chen CW, Yen HK, Lin YP, Lai CY, Wang JL, Groot OQ, Janssen SJ, Schwab JH, Hsu FM, Lin WH.
    Clin Orthop Relat Res; 2024 Dec 01; 482(12):2193-2208. PubMed ID: 39051924
    [Abstract] [Full Text] [Related]

  • 14. Enabling Systemic Identification and Functionality Profiling for Cdc42 Homeostatic Modulators.
    Malasala S, Azimian F, Chen YH, Twiss JL, Boykin C, Akhtar SN, Lu Q.
    bioRxiv; 2024 Jan 08. PubMed ID: 38260445
    [Abstract] [Full Text] [Related]

  • 15. Distinct metabolic phenotype renders β-catenin mutant hepatocellular carcinoma susceptible to treatment-induced ischemia.
    Weinfurtner K, Crainic JA, Tischfield D, Ackerman D, Kurian M, Woodard A, Li W, Gatmaytan I, Ostrowski D, Soulen MC, Dagli M, Shamimi-Noori S, Mondschein J, Sudheendra D, William Stavropoulos S, Reddy S, Khaddash T, Furth EE, Siegelman ES, Hunt SJ, Nadolski GJ, Kaplan D, Gade TPF.
    medRxiv; 2024 Nov 19. PubMed ID: 39606409
    [Abstract] [Full Text] [Related]

  • 16. The interplay between dysregulated metabolites and signaling pathway alterations involved in osteoarthritis: a systematic review.
    Aziz A, Ganesan Nathan K, Kamarul T, Mobasheri A, Sharifi A.
    Ther Adv Musculoskelet Dis; 2024 Nov 19; 16():1759720X241299535. PubMed ID: 39600593
    [Abstract] [Full Text] [Related]

  • 17. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
    Harnan S, Kearns B, Scope A, Schmitt L, Jankovic D, Hamilton J, Srivastava T, Hill H, Ku CC, Ren S, Rothery C, Bojke L, Sculpher M, Woods B.
    Health Technol Assess; 2024 Oct 19; 28(73):1-230. PubMed ID: 39487661
    [Abstract] [Full Text] [Related]

  • 18. STAT2/SLC27A3/PINK1-Mediated Mitophagy Remodeling Lipid Metabolism Contributes to Pazopanib Resistance in Clear Cell Renal Cell Carcinoma.
    Lu D, Li Y, Niu X, Sun J, Zhan W, Shi Y, Yu K, Huang S, Liu X, Xie L, Ma X, Liu B.
    Research (Wash D C); 2024 Oct 19; 7():0539. PubMed ID: 39600540
    [Abstract] [Full Text] [Related]

  • 19. Clofazimine inhibits small-cell lung cancer progression by modulating the kynurenine/aryl hydrocarbon receptor axis.
    Sharma G, Abdullah KM, Qais FA, Khan P, Cox JL, Sarwar T, Nasser MW, Batra SK, Siddiqui JA.
    Int J Biol Macromol; 2024 Dec 19; 282(Pt 3):136921. PubMed ID: 39490481
    [Abstract] [Full Text] [Related]

  • 20. RNAi Knockdown of EHMT2 in Maternal Expression of Prader-Willi Syndrome Genes.
    Zaric V, Kang HR, Rybalchenko V, Zigman JM, Gray SJ, Butler RK.
    Genes (Basel); 2024 Oct 24; 15(11):. PubMed ID: 39596566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.